Research ExplorerPublicationsLiver Cirrhosis as a Risk Factor for Direct-Acting Antiviral...

Liver Cirrhosis as a Risk Factor for Direct-Acting Antiviral Therapy Failure in Real-Life Hepatitis C Virus/Human Immunodeficiency Virus Coinfection

Standard

Liver Cirrhosis as a Risk Factor for Direct-Acting Antiviral Therapy Failure in Real-Life Hepatitis C Virus/Human Immunodeficiency Virus Coinfection. / Boesecke, Christoph; Ingiliz, Patrick; Berger, Florian; Lutz, Thomas; Schewe, Knud; Schulze Zur Wiesch, Julian; Baumgarten, Axel; Christensen, Stefan; Rockstroh, Jürgen K; Mauss, Stefan; GECCO Consortium.

In: OPEN FORUM INFECT DI, Vol. 4, No. 3, 2017, p. ofx158.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Boesecke, C, Ingiliz, P, Berger, F, Lutz, T, Schewe, K, Schulze Zur Wiesch, J, Baumgarten, A, Christensen, S, Rockstroh, JK, Mauss, S & GECCO Consortium 2017, 'Liver Cirrhosis as a Risk Factor for Direct-Acting Antiviral Therapy Failure in Real-Life Hepatitis C Virus/Human Immunodeficiency Virus Coinfection', OPEN FORUM INFECT DI, vol. 4, no. 3, pp. ofx158. https://doi.org/10.1093/ofid/ofx158

APA

Boesecke, C., Ingiliz, P., Berger, F., Lutz, T., Schewe, K., Schulze Zur Wiesch, J., Baumgarten, A., Christensen, S., Rockstroh, J. K., Mauss, S., & GECCO Consortium (2017). Liver Cirrhosis as a Risk Factor for Direct-Acting Antiviral Therapy Failure in Real-Life Hepatitis C Virus/Human Immunodeficiency Virus Coinfection. OPEN FORUM INFECT DI, 4(3), ofx158. https://doi.org/10.1093/ofid/ofx158

Vancouver

Boesecke C, Ingiliz P, Berger F, Lutz T, Schewe K, Schulze Zur Wiesch J et al. Liver Cirrhosis as a Risk Factor for Direct-Acting Antiviral Therapy Failure in Real-Life Hepatitis C Virus/Human Immunodeficiency Virus Coinfection. OPEN FORUM INFECT DI. 2017;4(3):ofx158. https://doi.org/10.1093/ofid/ofx158

Bibtex

@article{9083c7b5c6fe40fc8523e391472dbe3d,
title = "Liver Cirrhosis as a Risk Factor for Direct-Acting Antiviral Therapy Failure in Real-Life Hepatitis C Virus/Human Immunodeficiency Virus Coinfection",
abstract = "Current hepatitis C virus (HCV) treatment guidelines recommend treating HCV/human immunodeficiency virus (HIV)-coinfected individuals similar to HCV-monoinfected individuals. Recently inferior response rates to direct acting antiviral (DAA) therapy in HCV/HIV coinfection have been reported. Our German hepatitis C cohort (GECCO) cohort data show that coinfected patients with liver cirrhosis are less likely to achieve viral eradication.",
keywords = "Journal Article",
author = "Christoph Boesecke and Patrick Ingiliz and Florian Berger and Thomas Lutz and Knud Schewe and {Schulze Zur Wiesch}, Julian and Axel Baumgarten and Stefan Christensen and Rockstroh, {J{\"u}rgen K} and Stefan Mauss and {GECCO Consortium}",
year = "2017",
doi = "10.1093/ofid/ofx158",
language = "English",
volume = "4",
pages = "ofx158",
journal = "OPEN FORUM INFECT DI",
issn = "2328-8957",
publisher = "Oxford University Press",
number = "3",

}

RIS

TY - JOUR

T1 - Liver Cirrhosis as a Risk Factor for Direct-Acting Antiviral Therapy Failure in Real-Life Hepatitis C Virus/Human Immunodeficiency Virus Coinfection

AU - Boesecke, Christoph

AU - Ingiliz, Patrick

AU - Berger, Florian

AU - Lutz, Thomas

AU - Schewe, Knud

AU - Schulze Zur Wiesch, Julian

AU - Baumgarten, Axel

AU - Christensen, Stefan

AU - Rockstroh, Jürgen K

AU - Mauss, Stefan

AU - GECCO Consortium

PY - 2017

Y1 - 2017

N2 - Current hepatitis C virus (HCV) treatment guidelines recommend treating HCV/human immunodeficiency virus (HIV)-coinfected individuals similar to HCV-monoinfected individuals. Recently inferior response rates to direct acting antiviral (DAA) therapy in HCV/HIV coinfection have been reported. Our German hepatitis C cohort (GECCO) cohort data show that coinfected patients with liver cirrhosis are less likely to achieve viral eradication.

AB - Current hepatitis C virus (HCV) treatment guidelines recommend treating HCV/human immunodeficiency virus (HIV)-coinfected individuals similar to HCV-monoinfected individuals. Recently inferior response rates to direct acting antiviral (DAA) therapy in HCV/HIV coinfection have been reported. Our German hepatitis C cohort (GECCO) cohort data show that coinfected patients with liver cirrhosis are less likely to achieve viral eradication.

KW - Journal Article

U2 - 10.1093/ofid/ofx158

DO - 10.1093/ofid/ofx158

M3 - SCORING: Journal article

C2 - 28948181

VL - 4

SP - ofx158

JO - OPEN FORUM INFECT DI

JF - OPEN FORUM INFECT DI

SN - 2328-8957

IS - 3

ER -